Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) is the NASDAQ pre-market leader this morning on news that its subcutaneous SGI-110 interim phase I.II MDS and AML data demonstrated differentiated PK profile and good tolerability, as well as a preliminary promising complete responses in heavily pre-treated acute myelogenous leukemia patients enrolled in the Phase 1 segment of the trial.
The randomized Phase 1/2 first-in-human dose escalation study had 66 patients enrolled who were previously treated as of March 28, 2012.
In the data, two of the seven evaluable refractory AML patients with adequate hypomethylation with no prior resistance to hypomethylating agents showed a complete response and one patient showed partial response.
The pharmacokinetic data suggests delivery of decitabine by SGI-110 achieves high decitabine exposure. It also showed a longer half life and a potent dose-dependent hypomethylation induction in the daily regimen.
Shares are trading higher by 13.6% at $2.09 in the pre-market and the 52-week trading range is $1.51 to $3.35. The market cap before the news was a mere $171 million.
JON C. OGG
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.